mCRPC

Talazoparib Plus Enzalutamide for HRR Gene-Altered mCRPC Receives FDA Approval

Talazoparib Plus Enzalutamide for HRR Gene-Altered mCRPC Receives FDA Approval

SG Tylor

Source – FDA On June 20, 2023, the combination of talazoparib (Talzenna) and enzalutamide (Xtandi) has been approved by the ...